Anzeige
Mehr »
Mittwoch, 17.09.2025 - Börsentäglich über 12.000 News
Die Ethereum-Vorreiter: Wie Republic Technologies die Infrastruktur der Zukunft aufbaut
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3D54P | ISIN: US21833P3010 | Ticker-Symbol: 3371
Tradegate
16.09.25 | 17:08
8,850 Euro
+11,32 % +0,900
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
CORBUS PHARMACEUTICALS HOLDINGS INC Chart 1 Jahr
5-Tage-Chart
CORBUS PHARMACEUTICALS HOLDINGS INC 5-Tage-Chart
RealtimeGeldBriefZeit
8,6008,85016.09.
8,5008,80016.09.

Aktuelle News zur CORBUS PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiCorbus Pharmaceuticals Holdings, Inc. - 8-K, Current Report2
DiCorbus Pharmaceuticals Holdings, Inc.: FDA Grants Fast Track Designation to Corbus Pharmaceuticals' Nectin-4 Targeting ADC CRB-701 in Head and Neck Squamous Cell Carcinoma69Dose optimization data from the Phase 1/2 study to be presented next month at ESMO 2025Second Fast Track designation granted by FDA for CRB-701 NORWOOD, Mass., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Corbus...
► Artikel lesen
06.08.Corbus Pharma's Q2 Net Loss Widens16
CORBUS PHARMACEUTICALS Aktie jetzt für 0€ handeln
05.08.Corbus Pharmaceuticals Holdings, Inc. - 10-Q, Quarterly Report2
05.08.Corbus Pharmaceuticals Holdings, Inc. - 8-K, Current Report5
05.08.Corbus Pharmaceuticals GAAP EPS of -$1.44 misses by $0.082
30.07.Corbus Pharmaceuticals: Aktie profitiert von Zusage für ESMO-Kongress7
30.07.Corbus Pharmaceuticals stock rises after ESMO abstract acceptance3
30.06.Corbus begins multiple ascending dose portion of CRB-913 obesity trial3
30.06.Corbus Pharmaceuticals Holdings, Inc.: Corbus Pharmaceuticals Initiates Multiple Ascending Dose Portion of Phase 1 Study of Highly Peripherally Restricted CB1 Inverse Agonist CRB-913 for the Treatment of Obesity156No treatment-related neuropsychiatric events seen to date in SAD portion of Phase 1MAD study on track for completion in Q3 2025 NORWOOD, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals...
► Artikel lesen
25.06.Corbus Pharmaceuticals Holdings, Inc.: Corbus Pharmaceuticals Announces First Patient Dosed with its Nectin-4 Targeting ADC CRB-701 in Combination with Pembrolizumab224Combination cohort initiated following successful review of monotherapy cohortOver 100 participants dosed to-date in monotherapy cohortPriority are Head and Neck Squamous Cell Carcinoma (HNSCC) and...
► Artikel lesen
24.06.Corbus Pharmaceuticals Holdings, Inc.: Corbus Pharmaceuticals to Participate in the 3rd Annual Piper Obesity Symposium5
21.05.Mizuho cuts Corbus Pharma stock target to $32, keeps Outperform7
19.05.Corbus Pharmaceuticals Holdings, Inc. - 8-K, Current Report2
19.05.Corbus Pharmaceuticals names industry veteran Rachelle Jacques as board chair7
19.05.Corbus Pharmaceuticals Holdings, Inc.: Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair7
16.05.Is Small-Cap Corbus Pharma a Worthy Cannabis Investment?5
06.05.Corbus Pharmaceuticals Holdings, Inc. - 10-Q, Quarterly Report1
06.05.Corbus Pharmaceuticals Holdings, Inc. Q1 Loss Increases, Misses Estimates3
06.05.Corbus Pharmaceuticals Holdings, Inc. - 8-K, Current Report1
Weiter >>
29 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1